Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa.

Nature communications - 15 Aug 2023

Wu Yidong, Wan Xiaoling, Zhao Dongdong, Chen Xuxu, Wang Yujie, Tang Xinxin, Li Ju, Li Siwei, Sun Xiaodong, Bi Changhao, Zhang Xueli

Abstract excerpt

Base editing technology is an ideal solution for treating pathogenic single-nucleotide variations (SNVs). No gene editing therapy has yet been approved for eye diseases, such as retinitis pigmentosa (RP). Here, we show, in the rd10 mouse model, which carries an SNV identified as an RP-causing mutation in human patients, that subretinal delivery of an optimized dual adeno-associated virus system containing the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Electroretinography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Photoreceptor Cells

Share to Retina

Share to Retinitis Pigmentosa

Source

Open in PubMed Open full text

Identifiers

PMID: 37582961
DOI: 10.1038/s41467-023-40655-6
PMCID: PMC10427680

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa.PMID 37582961Read ↗

<i>In vivo</i> base editing rescues photoreceptors in a mouse model of retinitis pigmentosaSemantic proximity Read ↗

Correcting a patient-specific Rhodopsin mutation with adenine base editor in a mouse model.Semantic proximity Read ↗

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosisSemantic proximity Read ↗

Review: the history and role of naturally occurring mouse models with Pde6b mutations.Semantic proximity Read ↗

In vivo photoreceptor base editing ameliorates rhodopsin-E150K autosomal-recessive retinitis pigmentosa in mice.Semantic proximity Read ↗

Visual function restoration in a mouse model of Leber congenital amaurosis via therapeutic base editingSemantic proximity Read ↗

A gene-augmentation framework for selected early-stage autosomal recessive retinitis pigmentosa genotypesSemantic proximity Read ↗

Gene Therapy for Retinitis Pigmentosa: Current Challenges and New Progress.Semantic proximity Read ↗

Engineering single-AAV CRISPR-Cas13 RNA base editors for treatment of inherited retinal diseasesSemantic proximity Read ↗

Knockout and Replacement Gene Surgery to Treat Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa.Semantic proximity Read ↗

Nonviral base editing of KCNJ13 mutation preserves vision in a model of inherited retinal channelopathy.Semantic proximity Read ↗

CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.